The future of drug discovery and development: Shifting emphasis towards personalized medicine

The price of innovation: new estimates of drug development costs

Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski · Journal of Health Economics · 2003 · 4.3K citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +14

The power of business models

Scott M. Shafer, H. Jeff Smith, Jane C. Linder · Business Horizons · 2005 · 1.5K citations

Business, Strategic Management, Business Strategy +10

Timing of New Black Box Warnings and Withdrawals for Prescription Medications

Karen E. Lasser · JAMA · 2002 · 1K citations

Pharmacy, Pharmacology, Clinical Pharmacology +16

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation

Jeffrey L. Anderson, Benjamin D. Horne, Scott M. Stevens et al. · Circulation · 2007 · 730 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16